

PHARMCHEM

SWEAT-BASED DRUG TESTING

PharmChem, Inc. Announces Stock Repurchase Program

Fort Worth, TX (March 22, 2022) — PharmChem, Inc. (the “Company”) (OTC: PCHM) today announced that the Company's Board of Directors has approved a stock repurchase program under which the Company may repurchase up to 100,000 shares of its common stock at such times and such prices, as the Company considers to be in the best interests of the Company and its stockholders, subject to the availability of stock, general market conditions, alternative uses for capital, and the Company's financial performance, to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. This stock repurchase program has no expiration date and replaces the previous stock repurchase program.

About PharmChem, Inc.

PharmChem, Inc. (“PharmChem”) (OTC: PCHM), headquartered in Fort Worth, TX, is the manufacturer and sole source provider of the PharmChek® Drugs of Abuse Sweat Patch.

Forward-Looking Statements

Certain statements in this release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on our current expectations and assumptions regarding our business, the ability to develop products and strategies in order to meet the Company's long-term strategic goals, the economy, and other future conditions, including, but not limited to, the impact of the COVID-19 pandemic. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.